Ganoderma lucidum for Managing and Treating Dementia

View at publisher Summarise with VIRAT
Authors: Christopher Oloruntoba Akintayo, Tobi Opeyemi Olaleye, Oluwakemi Mary Olowomeye, Gloria Osayamen Omoruyi, Onyekweli Samuel, Akinsomisoye Olumide Stephen, Olaniyi Kehinde Samuel
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Dementia is a form of neurodegenerative disease with a high frequency, mental anomalies, memory loss, and cognitive impairment. Ganoderma lucidum, also called mushroom, possesses biologically active substances that have been shown to possess anti-inflammatory, anti-tumor, anti-aging, immunomodulatory, and antioxidant properties. According to recent research, G. lucidum and its constituents possess capacity against Alzheimer's disease (AD) from several angles, including the ability to improve quality of life, slow the disease's progression, and enhance cognitive performance. Inhibiting tau hyperphosphorylation, preventing Aβ production, influencing activated microglia, controlling the nuclear factor-kappa B (NF-κB)/mitogen-activated protein kinase (MAPK) signaling pathway, preventing neuronal death, modulating the immune system, and inhibiting acetylcholinesterase are the primary underlying mechanisms. The efficacy/potency of G. lucidum and its active ingredients for the management of AD was examined in this chapter, along with important aspects of mechanism research, clinical trials, and additional viewpoints. Because G. lucidum is a natural medicinal fungus effective against several pathophysiologies of AD, it has the potential to be developed as an adjuvant for AD treatment. Clinical studies and further mechanical research may be able to fully realize G. lucidum 's promise as an AD treatment.

Fields of Study & Subjects

Fungal Biology and Applications Alzheimer's disease research and treatments Medicinal Plants and Neuroprotection

Publication details

Journal / source
CRC Press eBooks
Pages
130–136
Publication date
31 March 2026
Language
EN
Document type
Book chapter